COST OF TREATMENT ANALYSIS OF BIOSIMILAR AND INNOVATOR INFlixIMAB IN A TERTIARY LEVEL HOSPITAL

Mondelo García C, Fernández Bargiela N, García Queiruga M, Feal Cortizas B, Lestón Vázquez M, Giménez Arufe V, Martín Herranz I

Servicio de Farmacia, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 84. 15006 A Coruña, Spain.

Background

- The availability of biosimilar infliximab (IFX) has been postulated to offer cost savings compared to innovator IFX, which could lead to patients being switched between products.

Purpose

- To analyze the demographic characteristics and pathologies of patients treated with infliximab and to evaluate the cost effectiveness of switching from innovator to biosimilar drug.

Material and methods

Observational retrospective six-month study. Sample: 100% patients treated with IFX. Data sources: electronic medical records (IANUS®), pharmaceutical application (SIMON®), management application (SINFHOS®) and pharmaceutical records.

Results

- 189 patients
- 616 prepared intravenous mixtures
- 131 patients with innovator IFX
  - 68 women (51.9%)
  - 63 men (48.1%)
  - Average age: 47.3 years-old (12-83)
  - Average weight: 71.7 Kg (48-132)
- 58 patients with biosimilar IFX
  - 32 women (55.2%)
  - 26 men (44.8%)
  - Average age: 42.5 years-old (8-72)
  - Average weight: 65.8 Kg (23-160 Kg)

- Diagnosis
  - Crohn disease: 31
  - Ulcerative colitis: 27
  - Psoriatic arthritis: 25
  - Rheumatoid arthritis: 23
  - Ankylosing spondylitis: 18
  - Psoriasis: 2
  - Others: 5

- Doses: 5 mg/kg
  - Number of patients: 81
- Doses: 3 mg/kg
  - Number of patients: 50

- Total expenditure: 686,505.40 €

Conclusions

- Biosimilar drugs are a good alternative compared with innovator drugs due to the saving which can be obtained with their use.
- Doing a close follow-up of the patients treated with biosimilar IFX would be very important to evaluate long term efficacy and safety of the treatment.